|
|
 Previous Article | Table of Contents | Next Article 
Evidence of a graft-versus-lymphoma effect associated with allogeneic bone
marrow transplantation
RJ Jones, RF Ambinder, S Piantadosi and GW Santos
Johns Hopkins Oncology Center, Johns Hopkins Medical Institutions,
Baltimore, MD 21205.
The existence of an immunologic antileukemia reaction associated with
allogeneic bone marrow transplantation (BMT) is well established. However,
a similar graft-versus-tumor effect against lymphomas has not been
demonstrated. We analyzed the results of BMT in 118 consecutive patients
with relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma. The
38 patients less than 50 years of age with HLA-matched donors had allogenic
marrow transplants, and the other 80 patients received purged autologous
grafts. The median age was 26 years in both the allogeneic and the
autologous graft recipients. The patient's response to conventional salvage
therapy before transplant was the only factor that influenced the
event-free survival after BMT (P less than .001). Both the patient's
response to salvage therapy before BMT (P less than .001) and the type of
graft (P = .02) significantly influenced the probability of relapse after
BMT. The actuarial probability of relapse in patients who responded to
conventional salvage therapy before BMT was only 18% after allogenic BMT
compared with 46% after autologous BMT. However, the actuarial probability
of event-free survival at 4 years was the same, 47% versus 41%, for
patients with responsive lymphomas who received allogeneic and autologous
transplants, respectively (P = .8). The beneficial antitumor effect of
allogeneic BMT was offset by its higher transplant-related mortality (P =
.01), largely resulting from graft-versus-host disease. Allogeneic BMT
appears to induce a clinically significant graft-versus- lymphoma effect.
The magnitude of this effect is similar to that reported against leukemias.
Volume 77,
Issue 3,
pp. 649-653,
02/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, et al.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann. Onc.,
November 1, 2008;
19(11):
1935 - 1940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al.
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
January 20, 2008;
26(3):
455 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica,
November 1, 2007;
92(11):
1533 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Majhail, D. J. Weisdorf, J. E. Wagner, T. E. Defor, C. G. Brunstein, and L. J. Burns
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma
Blood,
May 1, 2006;
107(9):
3804 - 3807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Molina, J. Zain, D. A. Arber, M. Angelopolou, M. O'Donnell, J. Murata-Collins, S. J. Forman, and A. Nademanee
Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides
J. Clin. Oncol.,
September 1, 2005;
23(25):
6163 - 6171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bellemare-Pelletier, J. Tremblay, S. Beaulieu, M.-R. Boulassel, J.-P. Routy, B. Massie, R. Lapointe, and J. Thibodeau
HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing
J. Leukoc. Biol.,
July 1, 2005;
78(1):
95 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res.,
September 15, 2004;
10(18):
6353S - 6359S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni, F. Patriarca, M. Boccadoro, F. Benedetti, et al.
Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells
J. Clin. Oncol.,
June 1, 2004;
22(11):
2172 - 2176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood,
February 1, 2004;
103(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Faulkner, C. Craddock, J. L. Byrne, P. Mahendra, A. P. Haynes, H. G. Prentice, M. Potter, A. Pagliuca, A. Ho, S. Devereux, et al.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Blood,
January 15, 2004;
103(2):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al.
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Blood,
November 15, 2003;
102(10):
3829 - 3836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Bishop
The Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity?
J. Clin. Oncol.,
October 15, 2003;
21(20):
3713 - 3715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Bierman, J. W. Sweetenham, F. R. Loberiza Jr, G. Taghipour, H. M. Lazarus, J. D. Rizzo, N. Schmitz, K. van Besien, J. M. Vose, M. Horowitz, et al.
Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
October 15, 2003;
21(20):
3744 - 3753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin, and I. F. Khouri
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
Ann. Onc.,
May 1, 2003;
14(5):
737 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
Blood,
January 15, 2003;
101(2):
441 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Robinson, A. H. Goldstone, S. Mackinnon, A. Carella, N. Russell, C. R. de Elvira, G. Taghipour, and N. Schmitz
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Blood,
December 15, 2002;
100(13):
4310 - 4316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al.
Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
J. Clin. Oncol.,
October 1, 2002;
20(19):
4022 - 4031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Guitart, S. C. Wickless, Y. Oyama, T. M. Kuzel, S. T. Rosen, A. Traynor, and R. Burt
Long-term Remission After Allogeneic Hematopoietic Stem Cell Transplantation for Refractory Cutaneous T-Cell Lymphoma
Arch Dermatol,
October 1, 2002;
138(10):
1359 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miura, C. J. Thoburn, E. C. Bright, W. Chen, S. Nakao, and A. D. Hess
Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD
Blood,
September 18, 2002;
100(7):
2650 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh
Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results
Arch Intern Med,
July 22, 2002;
162(14):
1558 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bellucci, E. P. Alyea, E. Weller, A. Chillemi, E. Hochberg, C. J. Wu, C. Canning, R. Schlossman, R. J. Soiffer, K. C. Anderson, et al.
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
Blood,
May 29, 2002;
99(12):
4610 - 4617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Akpek, R. F. Ambinder, S. Piantadosi, R. A. Abrams, R. A. Brodsky, G. B. Vogelsang, M. L. Zahurak, D. Fuller, C. B. Miller, S. J. Noga, et al.
Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma
J. Clin. Oncol.,
December 1, 2001;
19(23):
4314 - 4321.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. T. Ho and R. J. Soiffer
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood,
December 1, 2001;
98(12):
3192 - 3204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chambost, N. Van Baren, F. Brasseur, D. Godelaine, L. Xerri, S. J. Landi, I. Theate, J. Plumas, G. C. Spagnoli, G. Michel, et al.
Expression of gene MAGE-A4 in Reed-Sternberg cells
Blood,
June 1, 2000;
95(11):
3530 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Hematology,
January 1, 2000;
2000(1):
166 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Blood,
November 15, 1999;
94(10):
3325 - 3333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Parkman
The Future of Placental-Blood Transplantation
N. Engl. J. Med.,
November 26, 1998;
339(22):
1628 - 1629.
[Full Text]
|
|
|
|
|
|
|
K. van Besien, K. A. Sobocinski, P. A. Rowlings, S. C. Murphy, J. O. Armitage, M. R. Bishop, O.-k. Chaekal, R. P. Gale, J. P. Klein, H. M. Lazarus, et al.
Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma
Blood,
September 1, 1998;
92(5):
1832 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Chen, G. S. Chatta, W. D. Rubin, J. G. Clark, R. C. Hackman, D. K. Madtes, D. H. Ligitt, Y. Kusunoki, P. J. Martin, and M. A. Cheever
T Cells Specific for a Polymorphic Segment of CD45 Induce Graft-Versus-Host Disease with Predominant Pulmonary Vasculitis
J. Immunol.,
July 15, 1998;
161(2):
909 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Verdonck, A. W. Dekker, H. M. Lokhorst, E. J. Petersen, and H. K. Nieuwenhuis
Allogeneic Versus Autologous Bone Marrow Transplantation for Refractory and Recurrent Low-Grade Non-Hodgkin's Lymphoma
Blood,
November 15, 1997;
90(10):
4201 - 4205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ladenstein, R. Pearce, O. Hartmann, C. Patte, T. Goldstone, and T. Philip
High-Dose Chemotherapy With Autologous Bone Marrow Rescue in Children With Poor-Risk Burkitt's Lymphoma: A Report From the European Lymphoma Bone Marrow Transplantation Registry
Blood,
October 15, 1997;
90(8):
2921 - 2930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nagler, A. Ackerstein, R. Or, E. Naparstek, and S. Slavin
Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-alpha in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation
Blood,
June 1, 1997;
89(11):
3951 - 3959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Hess, E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, and M. J. Kennedy
Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide
Blood,
March 15, 1997;
89(6):
2203 - 2209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. S. Pavletic and J. O. Armitage
Bone Marrow Transplantation for Cancer--An Update
Oncologist,
June 1, 1996;
1(3):
159 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
